Skip to main content
. 2021 Aug 10;54(2):554–562. doi: 10.4143/crt.2021.375

Fig. 2.

Fig. 2

(A) Overall survival of patients treated with gemcitabine (red line) and patients treated with cisplatin (blue line). Overall survival was estimated by the Kaplan-Meier method, using log-rank. (B) Progression-free survival of patients treated with gemcitabine (red line) and patients treated with cisplatin (blue line). Progression-free survival was estimated by the Kaplan-Meier method, using log-rank.